

AMENDMENTS TO THE CLAIMS

The following listing of the claims replaces all prior versions and listings of claims in the application.

1-20. (Cancelled)

21. (Currently amended) A monoclonal antibody that recognizes an amyloid β that is the monoclonal antibody designated 1A10, ~~1G3~~, 82E1, or chimeric or humanized form of the antibodies designated 1A10, ~~1G3~~ or 82E1.

22. (Previously Presented) The monoclonal antibody of claim 21 that is the monoclonal antibody designated 1A10 or a chimeric or humanized form thereof.

23. (Previously Presented) The monoclonal antibody of claim 22 that is the humanized form of the monoclonal antibody designated 1A10.

24. (Previously Presented) The monoclonal antibody of claim 22 that is the monoclonal antibody designated 1A10.

25. (Previously Presented) A pharmaceutical composition comprising the monoclonal antibody of claim 22 and one or more pharmaceutically acceptable carriers or additives.

26. (Previously Presented) A method of treating a disease induced by accumulation of amyloid β comprising administering the monoclonal antibody of claim 22 to an individual in need of such treatment.

27. (Previously Presented) The method of claim 26 wherein said disease is Alzheimer's disease.

28. (Previously Presented) A method of inhibiting deposition of amyloid β comprising administering the monoclonal antibody of claim 22 to an individual in need of such inhibition.

29. (Previously Presented) A method of treating Alzheimer's disease comprising administering the monoclonal antibody of claim 23 to an individual in need of such treatment.

30-37. (Cancelled)

38. (Previously Presented) The monoclonal antibody of claim 21 that is the monoclonal antibody designated 82E1 or chimeric or humanized form thereof.

39. (Previously Presented) The monoclonal antibody of claim 38 that is the humanized form of the monoclonal antibody designated 82E1 4A40.

40. (Previously Presented) The monoclonal antibody of claim 38 that is the monoclonal antibody designated 82E1 4G3.

41. (Previously Presented) A pharmaceutical composition comprising the monoclonal antibody of claim 38 and one or more pharmaceutically acceptable carriers or additives.

42. (Previously Presented) A method of treating a disease induced by accumulation of amyloid β comprising administering the monoclonal antibody of claim 38 to an individual in need of such treatment.

43. (Previously Presented) The method of claim 42 wherein said disease is Alzheimer's disease.

44. (Previously Presented) A method of inhibiting deposition of amyloid β comprising administering the monoclonal antibody of claim 38 to an individual in need of such inhibition.

45. (Previously Presented) A method of treating Alzheimer's disease comprising administering the monoclonal antibody of claim 39 to an individual in need of such treatment.